silence-therapeutics.com (SLN) - Cash on Hand per Share

Liquid assets per share show a trend where the metric value is 3.98. Silence Therapeutics (SLN) leads in the application of RNA interference for cardiac therapy, leveraging the success of Zerlasiran and the support of major partners. Growth is driven by siRNA platform achievements and licensing payments, although high R&D costs coupled with a lack of profitability are depleting cash reserves.
Comprehensive metric breakdowns and analytics for Silence Therapeutics PLC (SLN)

Liquidity is critical for the biotech business of Silence Therapeutics (SLN) to sustain long-term R&D projects and patent protection. Analyzing cash per share allows for tracking the daily change in the physical capital balance per share, helping investors diagnose the depletion of reserves in a timely manner. This metric reflects the actual cash burn rate, determining the company's financial stability and the fair value of its assets.